| Customization: | Available |
|---|---|
| Transport Package: | Drum |
| Specification: | 99% |
|
Still deciding? Get samples of US$ 50/Piece
Request Sample
|
Suppliers with verified business licenses
Audited Supplier Audited by an independent third-party inspection agency
Ibandronate Sodium, with the CAS number 138844-81-2, is a bisphosphonate medication indicated for the treatment and prevention of postmenopausal osteoporosis. It works by inhibiting osteoclast activity, thereby reducing bone resorption and increasing bone mineral density. This helps to prevent bone loss and decrease the risk of fractures in patients with osteoporosis.
The chemical formula for Ibandronate Sodium is C9H24NNaO7P2, and it has a molecular weight of 343.23. It is typically administered orally in tablet form, with common dosages being 150 mg taken once a month or 2.5 mg daily. Ibandronate Sodium is also available for intravenous use, particularly for patients who cannot tolerate oral medications or for certain clinical indications such as hypercalcemia of malignancy.
When taken orally, Ibandronate Sodium must be swallowed whole with a full glass of water while the patient is in an upright position and followed by not lying down for at least 60 minutes to minimize esophageal irritation and potential adverse effects. It is important to maintain adequate calcium and vitamin D intake during therapy with Ibandronate Sodium to support bone health.
Common side effects of Ibandronate Sodium may include musculoskeletal pain, gastrointestinal reactions, and in rare cases, osteonecrosis of the jaw (ONJ), which is a serious condition affecting the bone of the jaw. Patients should be monitored for these potential side effects, especially those with a history of esophageal disorders or other gastrointestinal problems
){kind=link}